ストックスクリーナーアプリを入手
46.08
1.07%
-0.50
アフターアワーズ：
46.24
0.16
+0.35%
前日終値:
$46.58
開ける：
$46.63
24時間の取引高:
2.28M
Relative Volume:
0.58
時価総額：
$110.40B
収益：
$49.41B
当期純損益:
$5.59B
株価収益率:
19.30
EPS:
2.3875
ネットキャッシュフロー:
$8.32B
1週間 パフォーマンス:
-1.50%
1か月 パフォーマンス:
-3.46%
6か月 パフォーマンス:
-8.90%
1年 パフォーマンス:
-14.82%
1日の値動き範囲:
$46.07
$46.98
1週間の範囲:
$45.42
$46.98
52週間の値動き範囲:
$43.32
$55.73
Sanofi Adr Stock (SNY) Company Profile
Compare SNY vs LLY, JNJ, ABBV, AZN, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SNY
Sanofi Adr
|
46.08 | 110.40B | 49.41B | 5.59B | 8.32B | 2.3875 |
LLY
Lilly Eli Co
|
963.33 | 862.01B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
227.19 | 546.90B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
206.60 | 365.43B | 62.82B | 3.62B | 17.82B | 2.0331 |
AZN
Astrazeneca Plc
|
184.74 | 286.50B | 60.48B | 10.40B | 8.05B | 3.3297 |
NVS
Novartis Ag Adr
|
146.57 | 279.67B | 54.66B | 13.58B | 16.05B | 7.0171 |
Sanofi Adr Stock (SNY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-20 | ダウングレード | BNP Paribas Exane | Outperform → Neutral |
| 2026-02-12 | ダウングレード | BofA Securities | Buy → Neutral |
| 2026-01-27 | 開始されました | Citigroup | Neutral |
| 2026-01-16 | ダウングレード | UBS | Buy → Neutral |
| 2026-01-06 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2025-12-09 | ダウングレード | Guggenheim | Buy → Neutral |
| 2025-12-08 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2025-09-08 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-09-02 | アップグレード | Deutsche Bank | Hold → Buy |
| 2025-08-08 | アップグレード | JP Morgan | Neutral → Overweight |
| 2025-04-15 | 開始されました | Exane BNP Paribas | Outperform |
| 2025-03-21 | 開始されました | Goldman | Neutral |
| 2025-01-30 | アップグレード | Deutsche Bank | Sell → Hold |
| 2024-07-26 | 繰り返されました | Argus | Buy |
| 2024-01-23 | 開始されました | Morgan Stanley | Equal-Weight |
| 2024-01-16 | 再開されました | UBS | Buy |
| 2023-12-05 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2023-10-30 | ダウングレード | Stifel | Buy → Hold |
| 2023-09-06 | アップグレード | Berenberg | Hold → Buy |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-04-28 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2023-03-27 | アップグレード | Barclays | Equal Weight → Overweight |
| 2022-12-13 | 再開されました | Morgan Stanley | Overweight |
| 2022-08-12 | アップグレード | Deutsche Bank | Sell → Hold |
| 2022-08-09 | ダウングレード | UBS | Buy → Neutral |
| 2022-05-23 | 開始されました | SVB Leerink | Outperform |
| 2021-09-27 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2021-01-15 | 開始されました | Deutsche Bank | Sell |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-03-17 | アップグレード | Barclays | Underweight → Equal Weight |
| 2020-03-11 | アップグレード | Goldman | Neutral → Buy |
| 2020-02-11 | 開始されました | SVB Leerink | Mkt Perform |
| 2020-01-06 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-09-23 | アップグレード | Guggenheim | Neutral → Buy |
| 2019-09-20 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2019-09-03 | 開始されました | Bernstein | Outperform |
| 2019-08-14 | アップグレード | UBS | Neutral → Buy |
| 2018-12-11 | アップグレード | Jefferies | Hold → Buy |
| 2018-11-01 | アップグレード | Barclays | Underweight → Equal Weight |
| 2018-10-09 | 開始されました | Guggenheim | Neutral |
| 2018-09-10 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2018-08-10 | アップグレード | Citigroup | Neutral → Buy |
| 2018-03-23 | アップグレード | Liberum | Hold → Buy |
| 2018-01-23 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2017-12-06 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2017-12-01 | ダウングレード | Morgan Stanley | Overweight → Underweight |
| 2017-11-15 | アップグレード | Barclays | Underweight → Equal Weight |
| 2017-08-30 | アップグレード | HSBC Securities | Reduce → Hold |
すべてを表示
Sanofi Adr (SNY) 最新ニュース
Complement Inhibitors Market Outlook Remains Strong During the Forecast Period (2026–2036) with Increasing Adoption of C5 and C3 Targeted Drugs | DelveInsight - GlobeNewswire Inc.
Communiqué de presse : Assemblée Générale Annuelle du 29 avril 2026 - GlobeNewswire Inc.
SNY Stock Price, Quote & Chart | SANOFI-ADR (NASDAQ:SNY) - ChartMill
FDA Approval Broadens Dupixent Use While Sanofi Posts Earnings Beat - Sahm
Sanofi Eyes First On-Body Injector Cancer Therapy As FDA Delays Decision - Sahm
Earnings call transcript: Sanofi’s Q1 2026 earnings beat forecasts, stock rises - Investing.com
Earnings call transcript: Sanofi’s Q1 2026 earnings beat forecasts, stock rises By Investing.com - Investing.com Canada
Sanofi S.A. stock (FR0000127771): Is its biopharma pivot strong enough to unlock new upside? - AD HOC NEWS
Sanofi ADS (SNY) In-Depth Look | Sanofi ADS posts 4.6% EPS beat on pharma revenueADR - Newser
Sanofi S.A. stock (FR0000127771): Is its immunology pipeline strong enough to unlock new upside? - AD HOC NEWS
SNY Earnings History & Surprises | EPS & Revenue Results | SANOFI-ADR (NASDAQ:SNY) - ChartMill
Sanofi (SNY) Stock Price, News, Quote & History - Yahoo! Finance Canada
Morgan Stanley lowers Sanofi stock price target on FX update - Investing.com UK
Morgan Stanley lowers Sanofi stock price target on FX update By Investing.com - Investing.com Canada
AstraZeneca Strengthens Position In COPD Race With Successful Trials - Sahm
Sanofi ADR (NASDAQ:SNY) Presents a Classic Value Investment Case - ChartMill
Sanofi S.A. stock faces pressure amid dividend payout and sector headwinds on Euronext Paris - AD HOC NEWS
Medicare Chief Chris Klomp Optimistic On CDC Director Search As Vaccine Fight Roils Agency— 'We Will Select...' - Sahm
Federal Judge Flags Legal Flaws In RFK Jr.'s Vaccine Overhaul - Sahm
Sanofi (NASDAQ:SNY) Emerges as a Top Dividend Stock from Methodical Screening - ChartMill
Dupixent Leads the Charge for Sanofi's Strong Portfolio in Immunology, Vaccines, and Rare Diseases - Morningstar
MRNA Stock Gains After CHMP Endorses COVID-19-Influenza Combo Shot - Finviz
Antibiotics Market - GlobeNewswire Inc.
Sanofi (SNY) and Regeneron's Dupixent Recommended for EU Approval - Finviz
Kymera Q4 Loss Wider Than Expected, Cash Boost Extends Runway - Finviz
DNLI Q4 Loss Narrower Than Expected, Hunter Syndrome Drug in Focus - Finviz
Novavax Stock Gains as Q4 Earnings & Sales Beat Estimates - Finviz
How Do Investors Really Feel About Sanofi SA? - Sahm
CYTK Posts a Wider-Than-Expected Q4 Loss, Advances Myqorzo Launch Plans - Finviz
Sanofi Adr (SNY) 財務データ
収益
当期純利益
現金流量
EPS
1.39%
0.62%
大文字化:
|
ボリューム (24 時間):